Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dicerna submits IND application for DCR-PH1 therapeutic candidate
DCR-PH1 can be used to treat primary hyperoxaluria type 1 (PH1), which is a rare, inherited disorder of the liver that leads to kidney failure. It features small
DCR-PH1 can be used to treat primary hyperoxaluria type 1 (PH1), which is a rare, inherited disorder of the liver that leads to kidney failure. It features small
The drug is a potent, selective, brain penetrant and orally active 5-HT4 receptor partial agonist to treat cognitive dysfunction related with Alzheimer’s disease and other dementias. Suven Life
KU, which focuses on generic products, has 18 generic drugs in the market for conditions including attention deficit hyperactivity disorder (ADHD), gastroesophageal reflux disease, hypertension and respiratory disease.
Novartis said it can be used to treat adults with SAA who are either refractory to before immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem
Entolimod is a novel, broad-spectrum investigational drug being developed to mitigate the life-threatening consequences of a radiological attack. The Company has submitted an application for pre-Emergency Use Authorization
VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed to treat patients recovering from non-elective hip fracture surgery. Investigators have dosed the initial subjects
GSK’s two manufacturing facilities in Australia, its opiate product portfolio and inventory will be transferred to Sun Pharma. The acquired business includes analgesics produced from raw materials found
The deal will expand Audentes’ portfolio with the addition of Cardiogen’s lead program for the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT). No therapies have yet been
A BACE (beta-site APP-cleaving enzyme-1) inhibitor program will be developed and commercialized in AD. The lead molecule will be Novartis’ oral therapy CNP520 drug and additional compounds from
The company scaled up manufacturing process for Laccure Pessary product. A search has been started for a company interested in acquiring Laccure and launching the product. Laccure CEO